[HTML][HTML] Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia …
A Quintás-Cardama, H Kantarjian… - Journal of Clinical …, 2009 - ncbi.nlm.nih.gov
A Quintás-Cardama, H Kantarjian, T Manshouri, R Luthra, Z Estrov, S Pierce, MA Richie…
Journal of Clinical Oncology, 2009•ncbi.nlm.nih.govPegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in
Patients With Advanced Essential Thrombocythemia and Polycythemia Vera - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main
Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4881362 Other Formats PubReader PDF (151K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Patients With Advanced Essential Thrombocythemia and Polycythemia Vera - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main
Content Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4881362 Other Formats PubReader PDF (151K) Actions
Cite Collections Share Permalink Copy RESOURCES Similar articles Cited by other articles …
Abstract
Purpose
We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-α-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
ncbi.nlm.nih.gov
